Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia that is in Phase II/III clinical trial; 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma that is in Phase I clinical trial; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Frequently asked questions
What sector does Immunotech Biopharm Ltd (6978) operate in?
Immunotech Biopharm Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Immunotech Biopharm Ltd (6978) current stock price?
As of the latest data, Immunotech Biopharm Ltd stock price is HK$0.41, with a previous close of HK$0.40. Immunotech Biopharm Ltd gained HK$0.01 in the last trading session, representing a 2.5% increase.
What is Immunotech Biopharm Ltd (6978) current market capitalization?
Immunotech Biopharm Ltd market cap is approximately 253.18 million.
What is Immunotech Biopharm Ltd (6978) EBITDA?
Immunotech Biopharm Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -45.96 million.
Does Immunotech Biopharm Ltd (6978) pay dividends?
No. Immunotech Biopharm Ltd does not pay a dividend.
What is Immunotech Biopharm Ltd (6978) beta (volatility) score?
Immunotech Biopharm Ltd has a beta of 0.134, indicating lower volatility than the overall market.
